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have been measured with knowledge and satisfaction questionnaires, but have 
not been assessed within a choice-based methodology. The key function of a 
decision aid is to provide information for a patient to make an informed decision 
and the displaced activity within the health care system (the opportunity cost) 
would be physician consultation time. We propose a stated preference 
consultation time trade-off (CTTO) in which a proportion of a hypothetical 10-
minute physician consultation is traded for use of the decision aid by a patient 
with prior experience of the aid. Conceptually, a patient is trading a substitute 
source of health care information to maximise their utility of the consultation 
experience. The CTTO may be reported in consultation minutes or converted to a 
monetary value using the local cost of physician time. These values can be used, 
alongside the cost of the decision aid, for economic evaluation. The CTTO is 
currently being evaluated within a clinical trial of a cataract decision support 
tool.  
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Post-marketing non-interventional safety studies typically enroll patients at sites 
where patients receive care. During patient follow-up the occurrence of safety 
events of interest is recorded by site personnel based on information obtained 
from the patient during standard-of-care visits. Although this is the traditional 
approach for assessing the occurrence of safety events in the post marketing 
setting, it has several practical shortcomings, including; high cost associated 
with site start up, management, and data collection; infrequent or irregular 
standard-of-care visits; patients switching health care providers; transient 
nature of some safety events; treatment at non-study sites, and the lack of care-
seeking for the safety events. A design alternative that overcomes several  
of these short comings includes direct-to-patient contact and follow-up. In this 
approach, enrolled patients are regularly contacted via phone during follow-up 
and interviewed regarding the occurrence of safety events or potential signs  
and symptoms associated with the safety events. If either is reported by the 
patient, trained personnel follow up with the patient’s treating physician for 
further evaluation through phone interview and/or written confirmation of the 
safety event. We will present three examples of studies that make use of this 
direct-to-patient approach to capturing safety data. These studies comprise large 
multi-national and national studies with sample sizes ranging between 2000 to 
over 10,000 patients. In one study, the safety events include thromboembolotic 
and bleeding events in patients discharged from hospitalization for acute 
coronary syndrome. In two others, safety events comprise anaphylaxis, 
encephalitis, Bell’s palsy, neuritis, etc. associated with influenza vaccines. For 
each study, we will present specific design characteristics; procedures for patient 
contact, follow-up, and interviews; and procedures for confirming the 
occurrence of safety events. Strengths and weaknesses of the direct-to-patient 
approach will be discussed and recommendations regarding appropriate 
indications and safety events best suited to this novel methodology will be 
presented.  
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MPR AND PDC: IMPLICATIONS FOR INTERPRETATION OF ADHERENCE 
RESEARCH RESULTS  
Clancy ZA 
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OBJECTIVES: To compare and contrast the Medication Possession Ratio (MPR) 
and Proportion of Days Covered (PDC) measures of adherence and explore  
the implications of measure choice and specific definition on study results. 
METHODS: Two adherence measures, MPR and PDC, were selected for 
comparison because of their prominence in the claims database research 
literature. To highlight the effect of measure selection, examples demonstrating 
contrasting results for MPR and PDC are presented. Furthermore, the impact  
of numerator and denominator specification within each of those measures  
is examined and illustrated with examples. Implications for assessing  
and interpreting published research studies are presented. RESULTS: Although 
MPR and PDC have been operationally defined in similar ways in the literature, 
there are differences that could yield distinct results. The basic structure of these 
measures is a ratio with a proxy for the number of compliant days in  
the numerator and the number of days in a measurement period in  
the denominator. MPR is based on the sum of dispensed ‘days supply’ over  
a period, whereas PDC is based on evaluation of available supply for each 
individual day in the period. A demonstration is provided on how research 
design choices of MPR or PDC and specification of numerator and denominator 
can result in different findings for a given research question. CONCLUSIONS: 
Despite the similar structure of MPR and PDC metrics, study design choices  
can affect study results considerably. Selection of an adherence measure must 
be tailored to the therapeutic area, relevant medications, and research 
objectives. Researchers should be transparent in the specification of measures 
used and readers need to understand the implication of these research design 
decisions.  
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Opioid dependence incurs significant harm and associated economic costs 
worldwide. Whilst investment in medication-assisted treatment interventions 
cost-effectively reduces these harms, models of care for opioid dependence  
vary substantially between countries. Quantification of opioid-dependence 
treatment costs could help to optimise health policy decision-making regarding 
treatment provision. A health economic (HE) model was developed to calculate 
the costs associated with different treatment models of care in use across Europe 
allowing for comparison of different treatment systems. Total costs incurred, on 
a per-patient and national level, were calculated. A literature review was 
undertaken in order to find all relevant evidence on the treatment of opioid 
dependence. The HE model assesses direct costs (including medications, 
supervision and dispensing, staff costs, testing costs, other health care costs and 
miscellaneous costs) associated with the model of treatment in place in each 
country, according to national guidelines, and allows for comparison of the costs 
associated with different medication options. Local cost data were sourced by 
health economics groups in each of the relevant countries, and were drawn from 
publicly available databases and published literature where possible. Expert 
opinion was used to fill in any remaining data gaps. Seven countries were 
included in the analysis with the initial focus being Belgium, France, Germany, 
Italy, Portugal, Spain and UK. The primary output of the HE model, which will be 
presented, is the total per-patient cost of providing treatment for opioid 
dependence in each country. The HE model also provides the total cost of each 
treatment model in each country. Outputs are being validated against publicly 
available statistics on the total number of patients treated and the total cost to 
treat them, in each country. This HE model provides a tool to support 
discussions on and implementation of cost-effective models of care for opioid 
dependence around Europe.  
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The importance of incorporating patient-reported outcomes (PRO) assessment 
into the practice of medicine is well recognized. Measurement of PRO in real-
world clinical practice, however, is not commonly performed because of limited 
time spent with patients due to the busy schedules of clinicians, whose primary 
focus is to achieve a symptomatic cure. A post marketing safety surveillance 
(PMS) is one of a few opportunities to obtain non-interventional, prospective, 
real-world data about PRO, since PMS is a must due to regulatory requirements 
in many countries. Indeed, cross-continent planning and collaboration will be 
required to understand similarities and differences as PMS studies become a 
standard practice for multi-national research. Whereas PRO results are useful to 
evaluate patient-relevant effectiveness of the drug, the implementation of a PRO 
survey in PMS in different countries requires careful preparation, such as: 
facilitate multidisciplinary team communications for proper design of a PRO 
survey and selection of a validated survey questionnaire for all participating 
countries; strategize the recruitment of clinicians and patients; develop training 
materials for patient recruitment; handle adverse-event-like symptom questions 
in a questionnaire for adverse drug reaction reporting; develop the report format 
of PRO survey results to regulatory authorities; and develop a communication 
plan of PRO assessment results to stakeholders, such as physicians and patient 
organizations. We will discuss above issues associated with a PRO survey as a 
part of PMS from both Pharmacovigilance and Outcomes Research points of view 
based on our experience in Japan. A comparison will also be made about study 
planning with a PRO component between Japan and global PMS (such as the 
Post-Authorization Surveillance required by the European Medicines Agency), to 
highlight important lessons and implications for PRO researchers and 
practitioners to enhance the usage of PMS as a valuable opportunity to obtain 
real-world PRO assessments.  
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This session will illustrate how ePRO is a powerful approach for preventing 
missing data; explain how ePRO is more effective as compared to paper; and 
demonstrate how ePRO techniques can be implemented to prevent missing data. 
ePRO use can be an effective solution for preventing missing data as compared to 
paper data collection. Missing data is common in PROs and can result in 
significant problems for data analysis. While using a robust statistical plan for 
handling missing data is beneficial, studies still can suffer with high levels of 
missing data. One major contributing factor is the collection method. Many PROs 
are still administered in a traditional paper format which can result in high 
levels of missing data. This presentation will illustrate how ePRO can prevent 
missing data through providing examples of various ePRO techniques that can be 
implemented. Primary ePRO techniques to minimize missing data include: hard 
edit check to eliminate patients from skipping items or pages; reminders with 
real time technology to remind patients to complete their PROs; alerts to study 
staff of patient non-compliance; programmed logic to reduce erroneous entries 
and contradicting responses; time stamped data entry to ensure assessments are 
completed within the given window; and storage of directly entered data with 
back-up can ensure data is not lost. ePRO can prevent missing data, improve 
patient compliance and result overall in high quality data. ePRO eliminates many 
of the issues associated with data loss in traditional paper-based PRO systems. 
Future PRO development efforts should focus on creating more electronic 
versions of PRO instruments. Wider availability of ePRO instruments across 
therapeutic areas would ultimately result in high quality data and reduced 
missing data.  
